Sun Pharma Q4 Results: Cons profit rises 26% YoY to Rs 2,714 crore; board approves Rs 5/share dividend

Synopsis

Sun Pharma Q4 Results: Profit after tax (PAT) fell 19% sequentially during the quarter under review from Rs 3,369 crore in Q3FY26, while revenue declined 6% from Rs 15,520 crore reported in the October-December quarter of FY26.

Sun Pharmaceuticals on Friday reported a consolidated net profit of Rs 2,714 crore for the March-ended quarter, up 22% from Rs 2,150 crore in the year-ago period. The drugmaker also posted a 13% increase in revenue to Rs 14,612 crore in Q4FY26, compared with Rs 12,959 crore in the corresponding quarter of the previous financial year.

However, profit after tax (PAT) fell 19% sequentially during the quarter under review from Rs 3,369 crore in Q3FY26, while revenue declined 6% from Rs 15,520 crore reported in the October-December quarter of FY26.

The company’s board has declared a final dividend of Rs 5 per equity share, subject to shareholder approval at the 34th Annual General Meeting (AGM).

The company’s Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) for the quarter stood at Rs 3,954 crore, up 6.4% YoY, while the EBITDA margin stood at 27.1%.

The company’s exchange filing highlighted that global innovative medicines sales rose 20% to $354 million, accounting for 22.2% of overall sales.

FY26 takeaways

Sun Pharma Industries reported a strong consolidated performance in FY26, with revenue from operations rising 12.9% YoY to Rs 58,220 crore, driven by healthy growth across key domestic and global markets. The company’s Global Innovative Medicines business remained a key growth driver, with sales reaching $1.42 billion during the year.

Excluding milestone income, the innovative medicines segment registered a robust 16.4% growth and contributed 20.7% to the company’s overall sales, underscoring Sun Pharma’s increasing focus on specialty and differentiated products.

The pharmaceutical major reported a 16% year-on-year increase in EBITDA to Rs 17,731 crore, while EBITDA margin improved to 30.3%.

Net profit for FY26 stood at Rs 11,479 crore, marking a 5% increase over the previous financial year despite continued investments in expansion and research initiatives.

Sun Pharma spent Rs 3,554 crore on research and development (R&D) during FY26, with R&D investments accounting for 6.1% of total sales.

...moreless

...moreless